title: Novel function of scutellarin in inhibiting cell proliferation and inducing cell apoptosis of human Burkitt lymphoma Namalwa cells.
abstract: Anti-lymphoma therapy continues to present a major challenge. Even though cytotoxic therapy, immunotherapy and molecularly targeted therapy have been used in the clinic to treat the disease, effective anti-lymphoma drugs are still needed. In this study, we explored novel anti-lymphoma agents and found that scutellarin, an active component of a traditional Chinese medicinal herb Erigeron breviscapus, executed an anti-lymphoma effect. Scutellarin diminished the proliferation of B-lymphoma Namalwa cells in vitro and inhibited lymphoma growth in Namalwa cell-xenotransplanted mice without obvious toxicity. A mechanism study showed that scutellarin at doses of less than 10 μM induced cell cycle arrest at G0/G1 transition without the induction of cell apoptosis, which was accompanied by down-regulation of cyclin D1 and CDK4 expression. In contrast, scutellarin at concentrations of 15 μM or above promoted Namalwa cell apoptosis, which was partially associated with the activation of caspases. These results suggest that scutellarin is a new potential anti-lymphoma candidate.
authors.affiliation: Cyrus Tang Hematology Center, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, Jiangsu, China.
authors.forename: Yizhong
authors.initials: Y
authors.lastname: Feng
authors.forename: Shasha
authors.initials: S
authors.lastname: Zhang
authors.forename: Jian
authors.initials: J
authors.lastname: Tu
authors.forename: Zhifei
authors.initials: Z
authors.lastname: Cao
authors.forename: Yanyan
authors.initials: Y
authors.lastname: Pan
authors.forename: Bingxue
authors.initials: B
authors.lastname: Shang
authors.forename: Ruifang
authors.initials: R
authors.lastname: Liu
authors.forename: Meimei
authors.initials: M
authors.lastname: Bao
authors.forename: Pengda
authors.initials: P
authors.lastname: Guo
authors.forename: Quansheng
authors.initials: Q
authors.lastname: Zhou
mesh_terms: D000818:Animals; D047310:Apigenin / Q000737:chemistry / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D015153:Blotting, Western; D002051:Burkitt Lymphoma / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D059447:Cell Cycle Checkpoints / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D019938:Cyclin D1 / Q000235:genetics / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D049919:Erigeron / Q000737:chemistry; D005260:Female; D015870:Gene Expression; D005965:Glucuronates / Q000737:chemistry / Q000494:pharmacology*; D018922:HL-60 Cells; D006367:HeLa Cells; D006801:Humans; D019169:Jurkat Cells; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D015394:Molecular Structure; D008517:Phytotherapy; D020133:Reverse Transcriptase Polymerase Chain Reaction; D020298:U937 Cells; D023041:Xenograft Model Antitumor Assays
chemical_list: D005965:Glucuronates; D019938:Cyclin D1; C484876:scutellarin; D047310:Apigenin